Key result
Heparin-coated stents prevented thrombotic occlusions in a pig model (0% vs 40%, p<0.05), providing the rationale for the planned Benestent II pilot registry in 150 patients with angina pectoris.
Why the study?
Does elective implantation of a heparin-coated stent with delayed heparin infusion prevent thrombotic occlusion and bleeding complications in patients with angina pectoris?
Does elective implantation of a heparin-coated stent with delayed heparin infusion prevent thrombotic occlusion and bleeding complications in patients with angina pectoris?
Heparin-coated stents demonstrated thromboresistance in a preclinical pig model, providing the rationale for the Benestent II pilot trial to evaluate their safety and feasibility with reduced anticoagulation in humans.
No takes yet. Share an insight, caveat, or question.
Supports proceeding to human pilot registry with reduced anticoagulation; leaves open whether thromboresistance reduces occlusion or bleeding in angina patients.
Emanuelsson et al. (1994) studied Angina pectoris (n=150). Heparin-coated Palmaz-Schatz stent was evaluated on Incidence of acute and subacute thrombotic stent occlusion and vascular/bleeding complications within 30 days. Heparin-coated stents prevented thrombotic occlusions in a pig model (0% vs 40%, p<0.05), providing the rationale for the planned Benestent II pilot registry in 150 patients with angina pectoris.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: